A randomized, placebo-controlled trial of preemptive antifungal therapy for the prevention of invasive candidiasis following gastrointestinal surgery for intra-abdominal infections.

ABSTRACT:

Background

Patients undergoing emergency gastrointestinal surgery for intra-abdominal infection are at risk of invasive candidiasis (IC) and candidates for preemptive antifungal therapy.

Methods

This exploratory, randomized, double-blind, placebo-controlled trial assessed a preemptive antifungal approach with micafungin (100 mg/d) in intensive care unit patients requiring surgery for intra-abdominal infection. Coprimary efficacy variables were the incidence of IC and the time from baseline to first IC in the full analysis set; an independent data review board confirmed IC. An exploratory biomarker analysis was performed using logistic regression.

Results

The full analysis set comprised 124 placebo- and 117 micafungin-treated patients. The incidence of IC was 8.9% for

SUBMITTER: Knitsch W 

PROVIDER: S-EPMC4643488 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature